Uncategorized

[CARsgen Therapeutics] CARsgen Therapeutics announced that the New Drug Application of satricabtagene autoleucel, the autologous humanized Claudin18.2 CAR T-cell therapy product, was approved for the treatment of patients with Claudin18.2-positive, HER2-negative advanced gastric/ gastroesophageal junction adenocarcinoma who have failed at least two prior lines of therapy.

[Nature Immunology] Researchers showed that costimulatory domains control memory fate acquisition through asymmetric cell division. CD28 CAR T cells have higher CAR surface expression and enhanced surface proteome asymmetry after the first division, yet they show muted transcriptional and metabolic divergence between daughter cells.

[Blood Cancer Journal] The authors evaluated 63 acute myeloid leukemia (AML)-associated antigens for which CAR constructs have been reported. They provide a prioritized antigen landscape and a framework to guide the rational design of next-generation CARs for this challenging malignancy.

[Cancer Gene Therapy] Investigators explored how trefoil factor family (TFF) 3 signaling contributes to tumor progression and immune escape, and how its inhibition might reshape the tumor microenvironment to better support CAR-T cell activity.

[Molecular Therapy Oncology] Scientists investigated the potential of combining two oncolytic viruses, the human adenovirus B Goravir17, and type 3 mammalian orthoreovirus R12418 with CAR T cells targeting the two most promising diffuse midline gliomas targets, B7H3 and GD2.

[Science Advances] Researchers developed solid-tumor hallmark inducible, focused-ultrasound triggered enhanced reprogramming system (SHIFTERS), a platform designed to enable targeted and durable expression of clinically validated antigens in solid tumors,

[Nature Cancer] Scientists showed that rapid expansion of CAR-T cells after infusion is followed by a ‘diminution’ phase characterized by ferroptosis-associated features and elevated serum iron levels. In preclinical cancer models in female mice and ex vivo culture systems, excess intracellular iron impaired CAR-T cell function.

[Science Advances] The authors identified transmembrane emp24 domain-containing (TMED) as a key regulator of CD8+ T cell exhaustion and antitumor immunity. They showed that TMED4 deletion enhances the function of both CD8+ T cells and CAR T cells, improving their ability to resist exhaustion and eliminate tumors.

[Nature Communications] Researchers described a precision-engineered, cascade-targeted liposomal nanomedicine that enables in situ reprogramming of alveolar macrophages (AM) via a multi-step targeting strategy to generate functionally optimized chimeric antigen receptor-expressing AMs.

[ACS Nano] A nanovehicle fabricated using keratinocyte-derived apoptotic vesicles is proposed to enhance drug accumulation in dendritic cells (DCs) and synergistically modulate DC function.

[Nature Communications] Researchers mapped the fibroblast transcriptional response to stretching in vivo and demonstrated that stretching forces fibroblasts to exit their quiescent state and restart proliferation.

[Journal of Nanobiotechnology] Investigators aimed to enhance the targeted delivery efficiency of exosomes in skin tissues, systematically evaluated the therapeutic effects of hypoxia-preconditioned adipose-derived stem cell-derived exosomes in radiation-induced skin injury repair, and elucidated the underlying molecular mechanisms.